Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities and Exchange Commission, while outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate. The clinical-stage biopharmaceutical company said the annual report is available through the SEC and its investor relations website.
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing greater regulatory clarity as the company advances urcosimod toward a global Phase 3 pivotal study for neuropathic corneal pain (NCP). Chief executive Robert Dempsey said the FDA's feedback supports a streamlined development strategy that could allow the company to conduct a single-dose Phase 3 study with the potential to serve as a single pivotal trial.
FTSE 100 Live: Stocks called higher as Trump signals Iran ready for talks
FTSE 100 Live pre-open Blue-chip stocks in London and mainland Europe are set to rebound on Thursday after reports that the US and Iran could agree a new...
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from a US Food and Drug Administration Type D meeting that supports advancing its investigational therapy urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain (NCP). The clinical-stage biotechnology company said the FDA aligned with its proposed single-dose Phase 3 study design and provided feedback that could support a potential single-trial registration pathway, subject to successful study results and continued agency review.
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate targeting neuropathic corneal pain.
What Makes OKYO Pharma (OKYO) a New Buy Stock
OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuropathic corneal pain and inflammatory eye diseases.
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy urcosimod in a mid-stage study for neuropathic corneal pain (NCP), a chronic eye condition with no approved treatments. The clinical-stage biopharmaceutical company said the findings stem from an exploratory analysis of patient-reported outcomes in its Phase 2a trial and will be presented at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology.
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, scheduled for May 3 to 7 in Denver, Colorado. Chief scientific officer Dr Raj Patil is set to present the findings from OKYO's Phase 2a proof-of-concept clinical trial of urcosimod, a preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for NCP.
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
Analysts from Lucid Capital, H.C. Wainwright, and B.
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds of about $20 million. The clinical-stage biopharmaceutical company said it intends to use the net proceeds primarily to fund the clinical development of its product candidates, as well as for general corporate purposes and working capital.
OKYO Pharma appoints Flavio Mantelli as chief medical officer
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, has appointed Flavio Mantelli as its Chief Medical Officer. Dr Mantelli joins OKYO Pharma with extensive experience in ocular surface drug development, including leading the clinical development and global strategy for Oxervate at Dompé farmaceutici, which reached blockbuster status with sales exceeding $1 billion in 2024.
